Rare Disease, Alexion and Merck (MRK) announced positive topline results from the Phase 3 KOMET trial, a Phase 3 trial in ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

Kimberly-Clark Corporation today announced that Joseph Romanelli, president of Human Health International for Merck & Co., Inc., Rahway, NJ, USA, ("MSD") has been elected to its board of directors, ...

She previously served as Chief Executive Officer at Harpoon Therapeutics until the company’s acquisition by Merck in early 2024. In addition to Ms. Eastland’s appointment, Ingmar Bruns, M.D., has been ...

This adoption underscores TileDB's foundational role in advancing precision medicine through drug discovery pipelines ... Prior to joining Alexion in 2015, George was employed by Merck & Co., Inc. for ...

The Children’s Inn at the National Institutes of Health is breaking ground on a project that will allow the nonprofit to ...

Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company ...

The Children’s Inn at NIH, a private nonprofit that supports kids in clinical trials, just broke ground on a long-planned ...

The company describes the precision medicine test as the first of its kind to offer simultaneous ... Finally, the assay can ...

The market for multiplex biomarker imaging is anticipated to reach a valuation of USD 1,631.4 million by 2034, up from USD ...

In 2024, we established a license and research collaboration with MSD (tradename of Merck & Co., Inc., Rahway ... a target discovery collaboration with Johnson & Johnson Innovative Medicine. Our ...